Ikeda, Takanori
Ogawa, Satoshi
Kitazono, Takanari
Nakagawara, Jyoji
Minematsu, Kazuo
Miyamoto, Susumu
Murakawa, Yuji
Iwashiro, Sanghun
Kidani, Yoko
Okayama, Yutaka
Sunaya, Toshiyuki
Sato, Shoichiro
Yamanaka, Satoshi
Clinical trials referenced in this document:
Documents that mention this clinical trial
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
https://doi.org/10.1007/s11239-019-01934-6
Funding for this research was provided by:
Bayer Yakuhin LTD.
Article History
First Online: 20 August 2019
Compliance with ethical standards
:
: TI, SO, TK, JN, KM, SM and YM were advisory board members for Bayer Yakuhin, Ltd. TI received research grants from Daiichi Sankyo, Bristol-Myers Squibb, Medtronic Japan, St. Jude Medical and Bayer Yakuhin, Ltd., and honoraria from Daiichi Sankyo, Ono, Bayer Yakuhin, Ltd., Bristol-Myers Squibb and Pfizer and TI was an advisory board member for Bristol-Myers Squibb. TK received a research grant from Bayer Yakuhin, Ltd. JN received a research grant from Nihon Medi-Physics. KM received honoraria from Bayer Yakuhin, Ltd., Otsuka, Boehringer-Ingelheim, AstraZeneca, Pfizer, Mitsubishi-Tanabe, Japan Stryker, Kowa, Nihon Medi-Physics, BMS, Sawai, Sumitomo Dainippon, Dai-ichi Sankyo, Astellas and Nippon Chemiphar, and KM was an advisory board member for CSL Behring and Medico’s Hirata. SM received research grants from Takeda, CSL Behring, Meiji, MSD, Astellas, Eisai, Otsuka, Carl Zeiss Meditec, Philips Electronics Japan, Sanofi, Siemens Healthcare, Daiichi Sankyo, Mitsubishi-Tanabe, Chugai, Nihon Medi-Physics, Pfizer, Bristol-Myers Squibb, Brainlab, Mizuho and Medtronic. YM received research grants from Bayer Yakuhin, Ltd., Daiichi Sankyo and Boehringer-Ingelheim and honoraria from Bayer Yakuhin, Ltd., Daiichi Sankyo, Boehringer-Ingelheim and Bristol-Myers Squibb. SI, YK, YO, TS, SS and SY are employees of Bayer Yakuhin, Ltd.
: All procedures performed in the study were in accordance with the Good Post-marketing Study Practice standards of the Ministry of Health, Labour and Welfare in Japan.